Abstract:Objective To explore the therapeutic effect of selective antagonist-AM630 of cannabionid receptor 2 (CB2) in treatment of the titanium particles-induced inflammatory osteolysis. Methods Forty-five female BALB/c mice, 6-8 weeks old, were involved in the study, of which 15 mice were used as skull donors and the rest experimental animals were randomly divided into three groups, ie, black group, control group and treatment group, 10 mice per group.The mice model with air-pouch osteolysis induced by the titanium particles were established.The mice in the treatment group were injected with CB2 selective antagonist-AM630 (200 μg · kg-1 · d-1) intraperitoneally from two days before establishment of the air-pouch osteolysis model to two weeks after establishment of the model.Then, the mice were sacrificed and the pouch tissues were collected for molecular and histological analyses.The pouch membrane thickness and cell infiltration were tested by using computerized image analysis system and HE staining respectively.Osteoclast-like cells in the pouch membrane were determined by using tartrate-resistant acid phosphatase (TRAP) staining.Quantitative real-time polymerase chain reaction (RT-PCR) was employed to detect the mRNA levels of CB2, IL-1 β, TNF-α, receptor activator of NF-κB ligand (RANKL)and receptor activator of NF-κB (RANK).Results There exhibited apparent erythematous and oedematous changes in the control group, which was mitigated around the bone implants with AM630 treatment.Quantitative image analysis of the histological sections revealed significant difference of the pouch membrane thickness among three groups, (192.2 ± 19.4) μm in control group, (88.5 ± 14.7) μm in blank group and (122.1 ± 15.2) μm in treatment group (F = 101.74, P ＜ 0.05).Intensive TRAP staining was identified much in the control group but markedly reduced after AM630 treatment in the pouch tissues.RT-PCR showed that titanium particle stimulation could enhance the expressions of CB2, IL-1 β, TNF-α, RANKL and RANK gene in the air pouch tissues.However, the mRNA levels of these genes were markedly reduced after AM630 treatment, with statistical difference compared with control group (P ＜ 0.05). Conclusions CB2 selective antagonist AM630 can inhibit the process of titanium particlesstimulated inflammatory reaction and osteoclast activation.Therefore, CB2 represents a new suitable therapeutic candidate for the prevention and treatment of aseptic loosening of the artificial joint.

The Role of Cannabinoid Receptor 2 Selective Antagonist in Osteoclast Differentiation of RAW264.7 Cells

Cannabinoid Receptor-2 Selective Antagonist Negatively Regulates Receptor Activator of Nuclear Factor Kappa B Ligand Mediated Osteoclastogenesis

Inhibitory Effects of AM630 on Inflammatory Osteolysis Induced by Titanium Particles

[Effect of the Bone Resorption Supernatant from RAW264.7 Osteoclast on the Osteogenic Activity of Mouse MC3T3-E1 Cell].

Mineralizing Solution and Dexamethasone Enhance Receptor Activator for NF-κB Ligand Expression in Rat Bone Marrow Stromal Cells

The Effect of Alendronate on the Expression of Important Cell Factors in Osteoclasts

Role of Cannabinoid Receptor 2 Selective Antagonist in Titanium Particles-Induced Inflammatory Osteolysis

Effect of JAK2/STAT3 Signaling Pathway on RANKL-induced Osteoclastogenesis in RAW264.7 Cells

Inhibition Of Titanium Particle-Induced Inflammatory Osteolysis Through Inactivation Of Cannabinoid Receptor 2 By Am630

[Osteoclast Differentiation Regulated by Receptor Activator of Nuclear Factor Kappab Probably Through a Novel Signaling Pathway].

Evaluation of culture conditions for osteoclastogenesis in RAW264.7 cells

Recombinant Receptor Activator of Nuclear Factor Κb Exhibits More Marked Inhibitory Effects on Osteoclasts Compared with Recombinant Osteoprotegerin in Vitro and in Vivo.

Osteoclastogenesis in RAW264.7 Cells Induced by RANKL

The Study of RAW264.7 Cells Differentiate into Osteoclasts in Vitro

Effects of parthenolide on osteoclast differentiation of RAW264. 7 cell induced by receptor activator of ;nuclear factor κB ligand

Recombinant RANK Protein Inhibits Absorption Activity of Osteoclasts

Effects of Recombinant Human Osteoprotegerin and Recombinant RANK Protein on the Differentiation of Osteoclast Precursors

Comparative Characterization of Osteoclasts Derived From Murine Bone Marrow Macrophages and RAW 264.7 Cells Using Quantitative Proteomics

Differentiation of osteoclast-like cells induced by using different concentrations of M-CSF and RANKL

Carbon Monoxide Releasing Molecule 3 Inhibits Osteoclastogenic Differentiation of RAW264.7 Cells by Heme Oxygenase-1

Effect of Trans-resveratrol on the Differentiation of Osteoclast Induced from Bone Marrow in Mice